DESTINY-Endometrial01 Trial
Phase 3
600
about 5.9 years
18+
Female only
58 sites in AR, AZ, CA +28
What this study is about
Researchers are testing whether Trastuzumab Deruxtecan plus Rilvegostomig or Pembrolizumab, as a treatment, is more effective than chemotherapy (carboplatin + paclitaxel) plus Pembrolizumab for women with HER2-positive endometrial cancer. The trial will measure how long the treatment keeps the cancer from progressing.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Docetaxel
- 3.Take Paclitaxel
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, docetaxel, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), trastuzumab deruxtecan
infusion, injection, intravenous
Primary: Progression-free survival (PFS), as assessed by BICR
Secondary: Duration of response (DoR), as assessed by BICR and investigator, Objective response rate (ORR), as assessed by BICR and investigator, Overall Survival (OS), Overall survival (OS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test, Overall survival (OS) according to MMR status to determine the clinical utility of a MMR diagnostic test, Patient-reported tolerability, Pharmacokinetics of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig, Progression Free Survival (PFS) as assessed by the investigator
Oncology